Does transcatheter aortic valve replacement with the ACURATE neo2 platform improve short-term performance compared to Evolut PRO/PRO+ devices?
The ACURATE neo2 platform demonstrates similar short-term performance to Evolut PRO/PRO+ devices for transcatheter aortic valve replacement in this retrospective analysis.
This retrospective analysis reports a similar short-term performance of the ACURATE neo2 platform compared with the new-generation Evolut PRO/PRO+ devices. Randomised studies are needed to confirm our exploratory findings.
Baggio et al. (Sun,) studied this question.